Home > Publications > SATVI Research Papers Published

SATVI Research Papers Published

Since its establishment in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) has produced many high impact articles, documenting research findings in international journals and made presentations at a range of international conferences.

View the complete SATVI Bibiography on Pub Med . Click here.


2017-Publications published by SATVI authors in Peer-reviewed Journals during 2017
  Title Authors Journal
1 A novel blood test for tuberculosis prevention and treatment. Penn-Nicholson A, Scriba TJ, Hatherill M, White RG, Summer T. South African Medical Journal

Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol.

Bunyasi EW, Schmidt BM, Abdullahi LH, Mulenga H, Tameris M, Luabeya A,  Shenje J, Scriba TJ, Geldenhuys H, Robin Wood R, Hatherill M.

British Medical Journal.  2017; 10; 7(3):e014609

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB,  Fletcher HA, Hanekom WA, Wood R, McShane H, Scriba TJ, Hatherill M.  Lancet Respiratory Medicine. 2017; 5(4):282-290.
4 Long-lasting tuberculosis pleurisy. Petruccioli E, Scriba TJ, Petrone L, Hatherill M,  Cirillo DM, Joosten SA, Codecasa LG, Ottenhoff Th, Denkinger CM, Delia Goletti D.     European Respiratory Journal. 2017; 49(5).

Safety and immunogenicity of Adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial.

van Zyl-Smit RN, Esmail A, Bateman ME, Dawson R, Goldin J, van Rikxoort E, Douoguih M, Pau MG, Sadoff JC, McClain JB, Snowden MA, Benko J, Hokey DA, Rutkowski KT, Graves A, Shepherd B, Ishmukhamedov S,  Kagina B, Abel B, Hanekom WA, Scriba TJ, Bateman ED.     American Journal of Respiratory and Critical Care Medicine. 2017; 195(9):1171-1180.

The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG induced clinical and immunologic outcomes.

Graustein AD, Horne DJ, Fong JJ, Schwarz F, Mefford HC, Peterson GJ, Wells RD, Musvosvi M, Shey M, Hanekom WA, Hatherill M, Scriba TJ, Thuong NTT, Mai NTH, Caws M, Bang ND, Dunstan SJ, Thwaites GE, Varki A, Angata T, Hawn TR. Tuberculosis (Edinb). 2017; 104:38-45.

Antigen availability shapes T cell differentiation and function during tuberculosis



Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, Geldenhuys H, Smit E, Abrahams D, Rozot V, Dintwe O, Hoff ST, Kromann I, Ruhwald M, Bang P, Larson RP, Shafiani S, Ma S, Sherman DR, Sette A, Lindestam Arlehamn CS, McKinney DM, Maecker H, Hanekom WA, Hatherill M, Andersen P, Scriba TJ, Urdahl KB.   Cell Host & Microbe. 2017; 21(6):695–706.e5.

The CSF immune response in HIV-1-associated cryptococcal meningitis: macrophage activation, correlates of disease severity, and effect of antiretroviral therapy.   

Scriven JE, Graham LM, Schutz C, Scriba TJ, Wilkinson KA, Wilkinson RJ, Boulware DR, Urban BC, Meintjes G, Lalloo DG.    

Journal of Acquired Immune Deficiency Syndrome. 2017; 1; 75(3):299-307.

Mortality in severe Human Immunodeficiency Virus-Tuberculosis associates with innate Immune activation and dysfunction of monocytes.   

Janssen S, Schutz C, Ward A, Nemes E, Wilkinson KA, Scriven J, Huson MA, Aben N, Maartens G, Burton R, Wilkinson RJ, Grobusch MP, Van der Poll T, Meintjes G.   Clinical Infectious Disease Journal.  2017; 65(1):73-82.

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.

Bunyasi EW, Luabeya AKK, Tameris M, Geldenhuys H, Mulenga H, Landry BS, Scriba TJ, Schmidt BM,  Hanekom WA, Mahomed H, McShane H, Hatherill M.    

International Journal of Tuberculosis and Lung Disease. 2017; 21(7):778-783.


The cross-species mycobacterial growth inhibition assay (MGIA) project, 2010-2014.  


Brennan MJ, Tanner R, Morris S, Scriba TJ, Achkar JM, Zelmer A, Hokey D, Izzo A, Sharpe S, Williams A , Penn-Nicholson A, Erasmus M, Stylianou E, Hoft DF, McShane H, Fletcher HA. Clinical Vaccine Immunology Journal. 2017; 5; 24(9).

Identifying specificity groups in the T cell receptor repertoire

Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, Ji X, Han A,  Krams SM, Pettus C, Haas N, Arlehamn CSL, Sette A, Boyd SD, Scriba TJ, Martinez OM, Davis MM. Nature. 2017; 547(7661):94-98.

Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania

Amelio P, Portevin D, Reither K, Mhimbira F, Mpina M, Tumbo A, Nickel B, Marti H, Knopp S, Ding S,  Penn-Nicholson A, Darboe F, Ohmiti K, Scriba TJ, Pantaleo G, Daubenberger C, Perreau M.

PLOS Neglected Tropical Diseases.  2017; 11(7): e0005817.

Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis infection  


Nemes E, Rozot V, Geldenhuys H, Bilek N,  Mabwe S, Abrahams D, Makhethe L, Erasmus M, Keyser A, Toefy A, Cloete Y, Ratangee F, Blauenfeldt T, Ruhwald M, Walzl G, Smith B, Loxton AG, Hanekom WA, Andrews JR, Lempicki MD, Ellis R, Ginsberg AM, Hatherill M, Scriba TJ; the C-040-404 Study Team, and the Adolescent Cohort Study Team.
American Journal of Respiratory Critical Care Medicine. 2017; 196(5):638-648.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Beukes D, Van Reenen M, Zak DE, Mbandi SK, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F Mucosal Immunology. 2017; August 23.

A functional Toll-Interacting Protein variant is associated with Bacillus Calmette-Guérin-specific immune responses and tuberculosis.

Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, Cox JS, Daya M, Hoal EG, Lin L, Gottardo R, Hanekom WA, Scriba TJ, Hatherill M, Hawn TR. American Journal of Respiratory Critical Care Medicine. 2017; 15;196(4):502-511

Host blood RNA signatures predict the outcome of tuberculosis treatment.

Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE; Catalysis TB–Biomarker Consortium.

Tuberculosis (Edin). 2017; 107: 45-58


Differential recognition of Mycobacterium tuberculosis-specific epitopes as a function of tuberculosis disease history.

Scriba TJ, Carpenter C, Pro SC, Sidney J, Musvosvi M, Rozot V, Seumois G, Rosales SL, Vijayanand P, Goletti D, Makgotlho E, Hanekom W, Hatherill M, Peters B, Sette A, Arlehamn CSL. American Journal Respiratory Critical Care Medicine. 2017; 196(6):772-781.

Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population.

Baguma R, Penn-Nicholson A, Smit E, Erasmus M, Day J, Makhethe L, de Kock M, Hughes EJ, van Rooyen M, Pienaar B, Stone L, Hanekom W, Brennan MJ, Wallis RS, Hatherill M, Scriba TJ. PLoS One. 2017; 12(9) e0184563.
20 Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: a phase 2 randomized controlled trial. Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, Rose P, van der Zalm M, Mbaba S, Van As D, Hanekom WA, Walzl G, Scriba TJ, McShane H, Hatherill M; MVA029 Study Team. Clinical Infectious Diseases. 2017; September 26 (published online)

Polyfunctional CD4+ T cells as targets for tuberculosis vaccination.

Lewinsohn DA, Lewinsohn DM, Scriba TJ. Frontiers Immunology. October 5;8:1262.
22 TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development. Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; TBVAC2020 Consortium. Frontiers Immunology. 2017; 8:1262.

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE; other members of the ACS cohort study team. PLoS Pathogens. 2017;13(11):e1006687.

H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.

Mearns H, Geldenhuys HD, Kagina BM, Musvosvi M, Little F, Ratangee F, Mahomed H, Hanekom WA, Hoff ST, Ruhwald M, Kromann I, Bang P, Hatherill M, Andersen P, Scriba TJ; THYB04 study group. Vaccine. 2017 Jan 3;35(1):132-141.